Scott Dreyer compensation by year
COLLEGIUM PHARMACEUTICAL Summary Compensation Table · all 6 fiscal years held| Component | FY2018 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $356,692 | $418,635 | $440,265 | $462,281 | $489,507 | $523,236 |
| Bonus | $0 | $0 | $0 | $0 | $30,000 | $0 |
| Stock awards | $307,858 | $1,790,600 | $1,470,615 | $1,918,841 | $1,855,460 | $2,160,473 |
| Option awards | $1,110,651 | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $184,600 | $154,500 | $285,542 | $209,250 | $394,252 | $335,563 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $17,107 | $17,861 | $20,770 | $22,008 | $22,156 | $21,940 |
| Total | $1,976,908 | $2,381,596 | $2,217,192 | $2,612,380 | $2,791,375 | $3,041,212 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: COLLEGIUM PHARMACEUTICAL, INC DEF 14A filed April 7, 2026, accession 0001628280-26-024063, and prior-year filings. Open the filing on EDGAR.
How this page was built: the COLLEGIUM PHARMACEUTICAL, INC filed document, accession 0001628280-26-024063. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 50,938 | $2,358,429 | — |
| RSU | 41,918 | $1,940,803 | — |
| PSU | 30,870 | $1,429,281 | — |
| RSU | 28,334 | $1,311,864 | — |
| PSU | 18,000 | $833,400 | — |
| RSU | 13,125 | $607,688 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in COLLEGIUM PHARMACEUTICAL, INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments COLLEGIUM PHARMACEUTICAL discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $527,200 | $3,776,598 | $29,378 | $4,596,776 |
| Change in control and resignation for good reason | $790,800 | $8,481,466 | $44,067 | $9,711,733 |
| Resignation for good reason, no change in control | $527,200 | $3,776,598 | $29,378 | $4,596,776 |
| Change in control and involuntary termination | $790,800 | $8,481,466 | $44,067 | $9,711,733 |
Per the Potential Payments Upon Termination or Change in Control table in COLLEGIUM PHARMACEUTICAL, INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
COLLEGIUM PHARMACEUTICAL’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Dieter | Executive Vice President and General Counsel | $3,870,092 |
| Colleen Tupper | Executive Vice President and Chief Financial Officer | $3,515,055 |
| Scott Dreyer · this page | Executive Vice President and Chief Commercial Officer | $3,041,212 |
| Shirley Kuhlmann | Former Executive Vice President, Chief Administrative Officer, General Counsel and Secretary | $2,783,583 |
| Thomas Smith | Executive Vice President and Chief Medical Officer | $2,446,008 |
| Vikram Karnani | President and Chief Executive Officer | $1,715,846 |
Scott Dreyer's compensation dossier, COLLEGIUM PHARMACEUTICAL
You have read Scott Dreyer's totals and holdings. The dossier adds each equity grant COLLEGIUM PHARMACEUTICAL disclosed for Scott Dreyer and COLLEGIUM PHARMACEUTICAL's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full COLLEGIUM PHARMACEUTICAL compensation record
free company briefThis page is one person within COLLEGIUM PHARMACEUTICAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the COLLEGIUM PHARMACEUTICAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order COLLEGIUM PHARMACEUTICAL's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are COLLEGIUM PHARMACEUTICAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order COLL
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.